Sign in

    Peter Griffith

    Senior Equity Research Associate specializing in software sector analysis at Citigroup

    Peter Griffith is a Senior Equity Research Associate specializing in software sector analysis at Citigroup, where he supports research coverage on leading technology companies. With experience covering publicly traded software firms, he has contributed research and modeling that aids clients in understanding sector trends and company fundamentals, though public performance metrics and rankings are not yet available. Griffith joined Citi in October 2021 and previously held roles as an analyst, marketing agent, and claims specialist in both financial services and internet industries, following the completion of his MBA at Arizona State University’s W. P. Carey School of Business and a BS from the University of South Florida. He holds additional credentials as a Financial Modeling & Valuation Analyst from the Corporate Finance Institute.

    Peter Griffith's questions to VEEVA SYSTEMS (VEEV) leadership

    Peter Griffith's questions to VEEVA SYSTEMS (VEEV) leadership • Q4 2025

    Question

    Peter Griffith, on for Tyler Radke, asked about the typical product adoption pathway within the clinical suite for a customer after they have adopted EDC.

    Answer

    CEO Peter Gassner explained that adoption varies by customer. EDC and the clinical database (CDB) often go together. Success with EDC is a good indicator for future eCOA adoption, as those areas are closely related. However, he noted that other products like RTSM, Study Training, and Site Connect are more influenced by the adoption of eTMF and CTMS, not necessarily EDC.

    Ask Fintool Equity Research AI

    Peter Griffith's questions to CCC Intelligent Solutions Holdings (CCCS) leadership

    Peter Griffith's questions to CCC Intelligent Solutions Holdings (CCCS) leadership • Q4 2024

    Question

    Peter Griffith, on for Tyler Radke, asked about the timeline for achieving cross-selling success with EvolutionIQ, given only one overlapping customer, and if any changes to the selling motion are needed.

    Answer

    CEO Githesh Ramamurthy responded that the primary growth for EvolutionIQ is in its core markets of disability and workers' comp. He clarified that the main synergy is a product-level integration, where EvolutionIQ's medical summarization capability will be added to CCCS's Casualty solution suite and then sold by the traditional CCCS sales team. The single customer overlap is not the main focus of the synergy strategy.

    Ask Fintool Equity Research AI